Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 12, 2000, Pages 3451-3455

  Saves M ^a   Raffi, F ^a   Clevenbergh, P ^a   Marchou, B ^a   Waldner Combernoux, A ^a   Morlat, P ^a   Moing, V L ^a   Riviere C ^a   Chene G ^a   Leport, C ^a  

^a Faculté Xavier Bichat   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; PROTEINASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INCIDENCE; INFECTION RISK; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALANINE TRANSAMINASE; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATOCYTES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIVER; MALE; RISK FACTORS;

EID: 0034425846     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.12.3451-3455.2000     Document Type: Article

References (21)

1. Acute hepatitis in HIV-infected patients during ritonavir treatment
2. Severe hepatitis in three AIDS patients treated with indinavir
3. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
4. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
5. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine
6. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antoretroviral therapy
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
8. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
9. Is the combination of hepatitis and indinavir potentially dangerous
10. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
11. Toward the operational identification of adverse drug reactions
12. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir
13. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
14. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
15. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
16. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
17. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy
18. Indinavir-associated hepatitis in patients with advanced HIV infection
19. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy
20. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects